ijms-logo

Journal Browser

Journal Browser

Neurodegenerative Diseases and Protein Quality Control System

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 484

Special Issue Editor


E-Mail Website
Guest Editor
Department of Laboratory Medicine, Faculty of Medicine, Shimane University, 89-1 Enya Cho, Izumo 693-8501, Japan
Interests: neurodegeneration; Alzheimer’s disease; stroke; neurology

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons in specific brain regions. A hallmark of these conditions is the accumulation of misfolded and aggregated proteins, which disrupt cellular functions and significantly contribute to neuronal death. To counteract this, cells deploy sophisticated quality control systems such as molecular chaperones, the ubiquitin–proteasome system, autophagy, and the unfolded protein response. These mechanisms are crucial for ensuring proper protein folding and function, thereby preventing the harmful accumulation of misfolded proteins. The degradation of these aggregates through cell-mediated, enzymatic, and other clearance pathways is equally vital in the context of neurodegenerative diseases. For example, in AD, the enzymes responsible for the production of aggregation-prone amyloid β peptides, as well as their clearance mechanisms, are closely linked to the disease’s onset and progression. Understanding the intricate relationship between protein aggregation, the protein quality control system, clearance, and neurodegeneration is essential for developing new therapeutic strategies.

This Special Issue is dedicated to exploring the protein quality control system in the context of neurodegenerative diseases. Our aim is to elucidate the underlying mechanisms and highlight potential therapeutic strategies that could prove instrumental in managing these debilitating conditions.

Dr. Abdullah Sheikh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • Parkinson’s disease
  • amyotrophic lateral sclerosis
  • Huntington’s disease
  • autophagy
  • protein aggregation
  • ubiquitin–proteasome system
  • neurodegeneration
  • neuroinflammation
  • aggregated protein clearance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 13739 KiB  
Article
A Cationic Zn-Phthalocyanine Turns Alzheimer’s Amyloid β Aggregates into Non-Toxic Oligomers and Inhibits Neurotoxicity in Culture
by Abdullah Md. Sheikh, Shatera Tabassum, Shozo Yano, Fatema Binte Abdullah, Ruochen Wang, Takahisa Ikeue and Atsushi Nagai
Int. J. Mol. Sci. 2024, 25(16), 8931; https://doi.org/10.3390/ijms25168931 - 16 Aug 2024
Viewed by 173
Abstract
Amyloid β peptide (Aβ) aggregation and deposition are considered the main causes of Alzheimer’s disease. In a previous study, we demonstrated that anionic Zn-phthalocyanine (ZnPc) can interact with the Aβ peptide and inhibit the fibril-formation process. However, due to the inability of anionic [...] Read more.
Amyloid β peptide (Aβ) aggregation and deposition are considered the main causes of Alzheimer’s disease. In a previous study, we demonstrated that anionic Zn-phthalocyanine (ZnPc) can interact with the Aβ peptide and inhibit the fibril-formation process. However, due to the inability of anionic ZnPc to cross the intact blood–brain barrier, we decided to explore the interaction of cationic methylated Zn-phthalocyanine (cZnPc) with the peptide. Using a ThT fluorescence assay, we observed that cZnPc dose-dependently and time-dependently inhibited Aβ1-42 fibril levels under in vitro fibril-formation conditions. Electron microscopy revealed that it caused Aβ1-42 peptides to form small aggregates. Western blotting and dot immunoblot oligomer experiments demonstrated that cZnPc increased rather than decreased the levels of oligomers from the very early stages of incubation. A binding assay confirmed that cZnPc could bind with the peptide. Docking simulations indicated that the oligomer species of Aβ1-42 had a higher ability to interact with cZnPc. ANS fluorescence assay results indicated that cZnPc did not affect the hydrophobicity of the peptide. However, cZnPc significantly increased intrinsic tyrosine fluorescence of the peptide after 8 h of incubation in fibril-formation conditions. Importantly, cell culture experiments demonstrated that cZnPc did not exhibit any toxicity up to a concentration of 10 µM. Instead, it protected a neuronal cell line from Aβ1-42-induced toxicity. Thus, our results suggest that cZnPc can affect the aggregation process of Aβ1-42, rendering it non-toxic, which could be crucial for the therapy of Alzheimer’s disease. Full article
(This article belongs to the Special Issue Neurodegenerative Diseases and Protein Quality Control System)
Show Figures

Figure 1

Back to TopTop